Colorectal Cancer
Cancer of the colon or rectum — among the most common cancers worldwide and a major focus of screening and drug development.
Coverage of Colorectal Cancer is holding steady : 80 signals on the latest tracked day, up 36% from its three-week baseline of 59, across 3 domains (down from 9 a week ago). That makes it the #63 most-covered of the 337 concerns we track.
Colorectal Cancer is steady by its own history. Its normal rhythm is about 59 signals a day across 3 domains (32 tracked days). A real move would be a day at 74+ signals — 25% above that baseline, the bar our trend read calls accelerating — or a spread into domains beyond its usual 3. That is the move that would push it up the Wire. It sits on our Health & Bio Desk.
What’s changed
- A Tumor-Pituitary-Stromal Axis Promotes Colorectal Cancer Progression · crc-kras · 2026-09-21
- ctDNA in the Management of Resectable & Advanced Colorectal Cancer · crc-digest · 2026-09-20
- What Causes Colorectal Cancer in the Young? · crc-digest · 2026-09-20
- Non-Invasive Colorectal Cancer Screening Using Stool- and Blood-Based Tests · crc-digest · 2026-09-20
- National Cancer Institute: Colorectal Cancer · crc-digest · 2026-09-20
- A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer · PLOS ONE · 2026-09-20
What the reporting says
It shows up alongside Immunotherapy (232), KRAS (131), ctDNA (122), Braf (86), MSI-H (64), Egfr (63), Overall Survival (71), Wang (71).
Two steps out: AI (through Wang, 71 shared stories on the weaker link); China (through Wang, 71 shared stories on the weaker link); Lung Cancer (through Immunotherapy, 64 shared stories on the weaker link); FDA (through Immunotherapy, 54 shared stories on the weaker link).
Tracked since Oct 15, with coverage on 192 separate days — concentrated in Oncology and Pubmed Targeted.